Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 2;23(2):266-275.e6.
doi: 10.1016/j.stem.2018.05.020. Epub 2018 Jun 14.

Esrrb Unlocks Silenced Enhancers for Reprogramming to Naive Pluripotency

Affiliations
Free article

Esrrb Unlocks Silenced Enhancers for Reprogramming to Naive Pluripotency

Kenjiro Adachi et al. Cell Stem Cell. .
Free article

Erratum in

Abstract

Transcription factor (TF)-mediated reprogramming to pluripotency is a slow and inefficient process, because most pluripotency TFs fail to access relevant target sites in a refractory chromatin environment. It is still unclear how TFs actually orchestrate the opening of repressive chromatin during the long latency period of reprogramming. Here, we show that the orphan nuclear receptor Esrrb plays a pioneering role in recruiting the core pluripotency factors Oct4, Sox2, and Nanog to inactive enhancers in closed chromatin during the reprogramming of epiblast stem cells. Esrrb binds to silenced enhancers containing stable nucleosomes and hypermethylated DNA, which are inaccessible to the core factors. Esrrb binding is accompanied by local loss of DNA methylation, LIF-dependent engagement of p300, and nucleosome displacement, leading to the recruitment of core factors within approximately 2 days. These results suggest that TFs can drive rapid remodeling of the local chromatin structure, highlighting the remarkable plasticity of stable epigenetic information.

Keywords: DNA methylation; nucleosome; pioneer factor; pluripotency; reprogramming; silenced enhancer; transcription factor.

PubMed Disclaimer

Comment in